Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Non-randomized Trial of Stereotactic Ablative Radiotherapy (SABR) for Oligometastases

NCT02933242 is registered in ClinicalTrials.gov with British Columbia Cancer Agency as lead sponsor.

NCT NCT02933242
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02933242 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Non-randomized Trial of Stereotactic Ablative Radiotherapy (SABR) for Oligometastases
Lead sponsor
British Columbia Cancer Agency
Phase
Not applicable
Overall status
Active, not recruiting
Start date
November 30, 2016
Completion date
July 31, 2027
Enrollment
399 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic tumors